Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001699058 | SCV000235923 | likely benign | not provided | 2020-09-25 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000525610 | SCV000623870 | likely benign | Hypertrophic cardiomyopathy | 2023-12-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000620653 | SCV000735699 | likely benign | Cardiovascular phenotype | 2019-01-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000625203 | SCV000744117 | uncertain significance | Hypertrophic cardiomyopathy 17 | 2017-05-31 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003927714 | SCV004740143 | likely benign | JPH2-related disorder | 2022-01-16 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Clinical Genetics, |
RCV001699058 | SCV001924314 | uncertain significance | not provided | no assertion criteria provided | clinical testing |